Nuvalent (NUVL) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and strategy

• Focuses on structure-based drug design targeting clinically validated kinases, aiming to address unmet needs in oncology through innovative chemistry.

• Building a global, sustainable biotech company with capabilities in drug discovery, development, and delivery.

• Shifting to an independent global commercialization strategy, building ex-US infrastructure and recruiting leadership for international expansion.

• Strategic approach to ex-US launches, prioritizing geographies based on regulatory, pricing, and market access dynamics.

• Open to partnerships if they create more value, but currently focused on independent execution.

Regulatory and clinical progress

• NDA for zidesamtinib in TKI-pretreated ROS1-positive NSCLC accepted by FDA, with a PDUFA date of September 18 and US launch preparations underway.

• Data submission for TKI-naive ROS1 indication planned for the second half of the year, aiming for a line-agnostic extension.

• NDA for NVL-655 in TKI-pretreated ALK-positive NSCLC on track for submission in the first half of the year.

• Ongoing global phase 3 ALCAZAR study in TKI-naive ALK and phase 1b/2 HER2 exon 20 study in HER2-altered NSCLC.

• New development candidate expected to be disclosed by year-end.

Product differentiation and market opportunity

• Zidesamtinib uniquely targets ROS1 fusions and mutations, penetrates the CNS, and offers a well-tolerated profile, driving strong trial enrollment and commercial potential.

• NVL-655 demonstrates durable responses in ALK-positive NSCLC, with superior durability compared to lorlatinib, including in second-line settings.

• Both drugs show high CNS activity, a key differentiator in lung cancer treatment.

• ROS1 market could grow to resemble the current ALK market ($2B+), while ALK could expand toward the EGFR market ($4-6B).

• 65-70% of ALK and ROS1 market opportunity is ex-US, supported by strong global trial enrollment and demand.